ES2976011R1 - Proceso para preparar acido b-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-boronico e intermedios del proceso - Google Patents

Proceso para preparar acido b-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-boronico e intermedios del proceso Download PDF

Info

Publication number
ES2976011R1
ES2976011R1 ES202490026A ES202490026A ES2976011R1 ES 2976011 R1 ES2976011 R1 ES 2976011R1 ES 202490026 A ES202490026 A ES 202490026A ES 202490026 A ES202490026 A ES 202490026A ES 2976011 R1 ES2976011 R1 ES 2976011R1
Authority
ES
Spain
Prior art keywords
hidroxy
pentafluoropentyl
7alpha
17beta
estra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES202490026A
Other languages
English (en)
Other versions
ES2976011A2 (es
ES2976011B2 (es
Inventor
Roberto Lenna
Andrea Fasana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industriale Chimica SRL
Original Assignee
Industriale Chimica SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industriale Chimica SRL filed Critical Industriale Chimica SRL
Publication of ES2976011A2 publication Critical patent/ES2976011A2/es
Publication of ES2976011R1 publication Critical patent/ES2976011R1/es
Application granted granted Critical
Publication of ES2976011B2 publication Critical patent/ES2976011B2/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
ES202490026A 2021-10-29 2021-10-29 Proceso para preparar acido b-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-boronico e intermedios del proceso Active ES2976011B2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/060016 WO2023073413A1 (en) 2021-10-29 2021-10-29 PROCESS FOR PREPARING β-[(7α,17β)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID AND PROCESS INTERMEDIATES

Publications (3)

Publication Number Publication Date
ES2976011A2 ES2976011A2 (es) 2024-07-19
ES2976011R1 true ES2976011R1 (es) 2024-12-04
ES2976011B2 ES2976011B2 (es) 2025-05-12

Family

ID=78829715

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202490026A Active ES2976011B2 (es) 2021-10-29 2021-10-29 Proceso para preparar acido b-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-boronico e intermedios del proceso

Country Status (4)

Country Link
US (1) US20250136637A1 (es)
CH (1) CH720542B1 (es)
ES (1) ES2976011B2 (es)
WO (1) WO2023073413A1 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2017192991A1 (en) * 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2020187658A1 (en) * 2019-03-20 2020-09-24 Farmabios S.P.A. Process for the preparation of fulvestrant 3-boronic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202100008066A1 (it) * 2021-03-31 2022-10-01 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI ACIDO B-[(7α,17β)-17-IDROSSI-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONIL]ESTRA-1,3,5(10)-TRIEN-3-IL]-BORONICO E INTERMEDI DEL PROCESSO
IT202100012062A1 (it) * 2021-05-11 2022-11-11 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI ACIDO B-[(7α,17β)-17-IDROSSI-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTIL)SULFINIL]NONIL]ESTRA-1,3,5(10)-TRIEN-3-IL]-BORONICO E INTERMEDI DEL PROCESSO

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2017192991A1 (en) * 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2020187658A1 (en) * 2019-03-20 2020-09-24 Farmabios S.P.A. Process for the preparation of fulvestrant 3-boronic acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU JIAWANG ET AL. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). Journal of Medicinal Chemistry SEP 8 2016. , 08/09/2016, Vol. 59, Páginas 8134-8140 (DOI: 10.1021/acs.jmedchem.6b00753) Ver resumen y esquema 1. *

Also Published As

Publication number Publication date
CH720542B1 (it) 2025-09-15
US20250136637A1 (en) 2025-05-01
ES2976011A2 (es) 2024-07-19
WO2023073413A1 (en) 2023-05-04
ES2976011B2 (es) 2025-05-12

Similar Documents

Publication Publication Date Title
ES2955227R1 (es) Proceso para preparar ácido B-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-borónico
MX2019004519A (es) Sulfonacion de alcano libre de disolvente.
PL3963260T3 (pl) Sposób wytwarzania siarki pierwiastkowej i kwasu siarkowego
MX2019013657A (es) Metodo cosmetico para reducir las señales dermatologicas de envejecimiento.
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
BR112014015417A8 (pt) diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas
BR112015021955A2 (pt) implante cirúrgico
ES2948324R1 (es) Proceso para preparar (15alfa,16alfa,17beta)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol monohidrato (Estetrol monohidrato)
MX2014010340A (es) Sulfonamidas de aza-aril 1h-pirazol-1-il benceno.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
ES2957913R1 (es) Proceso para la preparación de ácido B-[(7alfa,17beta)-17-hidroxi-7-[9-[(4,4,5,5,5-pentafluoropentil)sulfinil]nonil]estra-1,3,5(10)-trien-3-il]-borónico e intermedios de dicho proceso
CO2018006041A2 (es) Formulaciones y métodos para controlar el ciclo reproductivo y la ovulación
CL2012000713A1 (es) Metodo para tratar o prevenir un transtorno afectado por la liberacion reducida o nula de una hormona intestinal segregada desde las celulas l, estimulando su produccion en el colon; y composicion utilizada que comprende ac, butirico, ac. biliar, ac. graso de cadena larga o glutamina y un inhibidor de la recaptacion de monoamina.
IL277016A (en) Acid reflux treatment formulations that include sodium alginate
BR112018071639A2 (pt) processo para produção de metil mercaptano a partir de sulfeto de dimetila
EP4135772A4 (en) Controlled release hyaluronic acid compositions
ZA201808449B (en) Process for pd-catalyzed hydroxycarbonylation of diisobutene: ratio of 3,5,5-trimethylhexanoic acid / h2o
EP4004147A4 (en) HEAT TREATMENT PROCESS AND SYSTEM FOR INCREASED PITCH YIELDS
BR112017025029A2 (pt) ?novo fragmento fab de anticorpo ngf anti- humano?.
PL3717402T3 (pl) Sposób wytwarzania siarki i kwasu siarkowego
PT3700506T (pt) Formulações tópicas para tratar distúrbios dermatológicos incluindo calvíce de padrão masculino
BR112017013145A2 (pt) processos para recuperação de ácido a partir de uma solução aquosa rica em ácido, processo para recuperação de ácido sulfúrico a partir de uma solução aquosa rica em ácido sulfúrico, e solução de ácido recuperada
MX2016015528A (es) Composiciones secadas por pulverizacion que tienen diferentes perfiles de disolucion y procesos para su preparacion.
AR092393A1 (es) Retardador de fraguado para preparaciones de cemento y proceso para su fabricacion
PT4041186T (pt) Composição farmacêutica anidra para tratamento de manutenção da psoríase

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2976011

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20240719

EC2A Search report published

Ref document number: 2976011

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20241127

FG2A Definitive protection

Ref document number: 2976011

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20250512